Ilaris
Ilaris is the brand name for canakinumab, a human monoclonal antibody that inhibits interleukin-1 beta (IL-1β). It is a biologic therapy developed by Novartis and used to treat certain autoinflammatory diseases driven by IL-1β–mediated inflammation.
Indications for Ilaris include cryopyrin-associated periodic syndromes (CAPS), which encompasses conditions such as familial cold autoinflammatory
Mechanism and administration: Ilaris works by binding IL-1β, preventing it from signaling through the IL-1 receptor
Safety and monitoring: Potential adverse effects include increased susceptibility to infections, neutropenia, injection-site reactions, abdominal pain,